Cariprazine hydrochloride, CAS 1083076-69-0, chemical name trans-N-{4-[2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl]cyclohexyl}-N,N'-dimethylurea hydrochloride, molecular formula C21H33Cl3N4O, and relative molecular mass 463.87, is the specified pharmaceutical-grade active pharmaceutical ingredient for tablet, capsule, granule, and injectable dosage forms. The product model is the hydrochloride salt of the atypical antipsychotic, not the free base; salt selection influences aqueous solubility, dissolution, and solid-state handling. Release and stability specifications for this material are established under ICH Q6A and ICH Q7, with impurity thresholds derived from ICH Q3A, residual solvents from ICH Q3C, elemental impurities from ICH Q3D, and stability data generated per ICH Q1A(R2). Because a compendial monograph may not be adopted in every jurisdiction at the time of manufacture, the certificate of analysis is typically aligned with pharmacopoeial general methods including USP <621>, <467>, <921>, <281>, <232>, <233>, and Ph. Eur. 2.2.29, 2.4.24, 2.5.12. For oral solid dose applications, particle size, bulk density, and powder flow are controlled as critical material attributes; for injectable applications, bioburden and bacterial endotoxin limits are tightened. The API is manufactured under ICH Q7 GMP and intended for further processing by qualified drug product manufacturing sites under 21 CFR 210 and 211; it is not supplied as a sterile final dosage form. A representative release specification framework is summarized in Table 1.

How Does the Solid-State Form Influence Tablet and Capsule Manufacture?

The crystalline form of cariprazine hydrochloride is a critical quality attribute because milling, wet granulation, drying, and compression can alter polymorphic composition, amorphous content, and particle size distribution. XRPD per USP <941> and Ph. Eur. 2.9.33 is used to confirm the designated crystalline form before release. Micronization may increase amorphous content at particle surfaces; if the amorphous fraction exceeds the formulation-specific threshold, the powder can undergo recrystallization, caking, or altered dissolution. Published industrial data on the solid-state conversion kinetics of cariprazine hydrochloride under specific wet granulation conditions is limited; therefore, formulation-specific XRPD and dynamic vapour sorption data are required. Particle size D90 and span are measured by laser diffraction using USP <429> or ISO 13320:2020; micronized material with D90 ≤10 µm increases surface area but may reduce flow and increase electrostatic adhesion. The flow consequence is quantified by bulk density, tapped density, Hausner ratio, and Carr index per USP <616> and Ph. Eur. 2.9.34. A Hausner ratio above 1.35 generally indicates poor powder flow and may require wet granulation, slugging, or roller compaction. Water content is controlled at ≤0.5% by USP <921> or Ph. Eur. 2.5.12 because higher residual moisture can plasticize amorphous regions and accelerate form instability. During high-shear granulation with water, the API may undergo partial dissolution and recrystallization; the dried granule must therefore be rechecked by XRPD. The hydrochloride salt is not intrinsically free-flowing after micronization, so dry blending with colloidal silicon dioxide at 0.5–1.0% w/w or equivalent glidant levels is commonly evaluated. Tablet and capsule content uniformity is monitored by USP <905>, and dose proportionality is supported by blend uniformity sampling using USP <601> where applicable.

For long-term storage and shipment, the API is normally packed in double polyethylene bags inside a sealed aluminium-laminated bag with desiccant and stored in a light-resistant, tight container at controlled room temperature or 2–8 °C as specified by the stability protocol. The hydrochloride salt is hygroscopic to a degree that is quantified by dynamic vapour sorption; exposure to relative humidity above 60% may increase water uptake and reduce flowability, so opening of primary containers should occur in low-humidity suites or under nitrogen. Stability testing per ICH Q1A(R2) uses long-term, intermediate, and accelerated zones; batch-to-batch variance in residual solvents and water should be trended because they influence weight loss on drying and assay correction. Retest intervals are assigned from ongoing stability data, not from fixed shelf life. Incompatibilities with amine-based excipients or strong nucleophiles in granulating fluids should be assessed via forced degradation because the hydrochloride salt can undergo hydrolysis of the urea bridge or oxidation of the piperazine ring under extreme pH. The material is not a finished pharmaceutical; it must not be weighed in open production areas without local exhaust ventilation and a dust-tight containment system.

When Injectable Grade Requires Aseptic Processing and Endotoxin Control

Aseptic manufacturing lines for injectable cariprazine impose additional release controls that surpass oral grade requirements. The API for parenteral formulation is not necessarily sterile, but it must support downstream aseptic filtration through a validated 0.22 µm membrane without excessive particle load or viscosity. Bacterial endotoxins are controlled at ≤0.5 EU/mg using USP <85> or Ph. Eur. 2.6.14; bioburden is controlled at ≤10 CFU/g by USP <61> and <62>. Elemental impurities are tightened to ICH Q3D parenteral PDEs, for example cadmium ≤2 µg/day, lead ≤5 µg/day, and palladium ≤10 µg/day when palladium catalysis is used in the synthetic route; these values translate into concentration limits based on the maximum daily injectable dose. Residual solvents are governed by ICH Q3C, with lower class 2 limits applied if the daily injectable dose is high. The API dissolution matrix for parenterals requires pH adjustment and may involve an acidifying agent; precipitation during dilution with saline or phosphate buffers must be avoided because cariprazine hydrochloride can exhibit pH-dependent solubility with reduced solubility at neutral pH. Particulate matter in the final injectable product is tested per USP <787> or <788>; visible particles are controlled by 100% inspection following 21 CFR 211.84. Terminal sterilization of the final drug product is acceptable only if validated by heat penetration and stability data; otherwise aseptic filtration followed by liquid filling or lyophilization is used. Batch-to-batch variability in particle size and microbial quality can cause filter clogging; filter compatibility testing with the API solution at process temperature and drug concentration is required. The injectable grade is therefore not simply the oral API tested to a lower endotoxin limit; it requires a distinct release protocol that integrates low bioburden, low endotoxin, controlled particulate matter, and documented filtration performance.

Granule, Tablet, and Capsule Process Variables at the API Interface

During high-shear granulation or roll compaction, the particle size and bulk density of cariprazine hydrochloride influence granule growth, downstream flow into tablet dies, and capsule slug weight. The API is typically dry-blended with diluents and disintegrants before granulation; if the API D90 is above 30–50 µm, content uniformity risk increases in low-dose strengths, and USP <905> acceptance value monitoring is used. For micronized material with D90 ≤10 µm, electrostatic cohesion may reduce flow, and a wet granulation step with 0.5–2.0% w/w binder solution may be required; the precise level is formulation-dependent. Roller compaction can densify the blend and reduce segregation but may also reduce tablet tensile strength if overcompaction is used. On production-scale high-shear granulators with impeller speeds of 200–500 rpm and chopper speeds of 1500–3000 rpm, micronized APIs of this class can adhere to the granulator lid and cause blade build-up; published data for the specific cariprazine configuration is limited. For capsule filling, powder flow is characterized by bulk density, tapped density, Hausner ratio, and Carr index per USP <616>; a Hausner ratio above 1.35 generally indicates poor flow and may require densification. Granulation with water is evaluated for polymorphic form shift by XRPD after drying because water activity can mediate recrystallization. Disintegration and dissolution of tablets and capsules are controlled by granule porosity, not only API particle size, and are tested per USP <701> and <711>. Higher residual moisture above the specified limit can soften granules and alter granule size distribution. Capsule fill weight variation is controlled by powder flow and bulk density; low bulk density can cause short fills, while high bulk density can reduce the available fill volume and require smaller capsule shells or lower dose per shell.

Differences in Receptor Binding Profiles Relative to Aripiprazole and Brexpiprazole

The receptor binding signature of cariprazine hydrochloride differs from structurally related atypical antipsychotics in the D3/D2 rank order. Cariprazine is a partial agonist at D2 and D3 dopamine receptors, with higher in vitro affinity for D3 than D2L; published radioligand binding data report Ki values of approximately 0.085 nM at D3 and 0.49 nM at D2L. Aripiprazole, by comparison, shows Ki values of approximately 0.8 nM at D3 and 0.34 nM at D2L, while brexpiprazole shows approximately 1.1 nM at D3 and 0.30 nM at D2L. The structural distinction for the API is also significant: cariprazine contains a 2,3-dichlorophenyl piperazine and a trans-cyclohexyl urea side chain, whereas aripiprazole is a quinolinone derivative and brexpiprazole is a benzo[b]thiophene derivative. Within all three molecules, salt form, particle size, residual solvent profiles, and solid-state controls are product-specific and do not transfer from one API to another. Table 2 summarizes the comparative binding values as reported in public literature; these values are assay-system dependent and should not be interpreted as clinical potency without exposure-receptor occupancy data. The product designation “Cariprazine Hydrochloride Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” therefore identifies a single salt and route-compatible grade, not a biological or clinical comparator.